Moreover, PAIB-SOs are designed to reduce the side effects often found with classic antimitotics by targeting BC cells that express CYP1A1 limiting undesired outcomes in healthy CYP1A1-deficient cells and tissues. The gene discussed is CYP1A1; the disease is breast cancer.